Kyowa Kirin Co., Ltd. (FRA:KY4)

Germany flag Germany · Delayed Price · Currency is EUR
14.00
0.00 (0.00%)
Last updated: Dec 4, 2025, 9:59 AM CET
-9.68%
Market Cap 7.38B
Revenue (ttm) 2.78B
Net Income (ttm) 210.60M
Shares Out n/a
EPS (ttm) 0.40
PE Ratio 35.02
Forward PE n/a
Dividend 0.35 (2.46%)
Ex-Dividend Date Jun 27, 2025
Volume n/a
Average Volume 13
Open 14.10
Previous Close 14.00
Day's Range 14.00 - 14.10
52-Week Range 12.30 - 15.50
Beta n/a
RSI 54.76
Earnings Date Feb 9, 2026

About Kyowa Kirin

Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachro... [Read more]

Industry Pharmaceutical Preparations
Founded 1949
Employees 5,669
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol KY4
Full Company Profile

Financial Performance

In 2024, Kyowa Kirin's revenue was 495.56 billion, an increase of 12.06% compared to the previous year's 442.23 billion. Earnings were 59.87 billion, a decrease of -26.26%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.